Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase for Hyperuricemia in Pediatric Patients with Tumor Lysis Syndrome Risk
NCT00302653Phase 4Completed
- Sponsor
- Sanofi
- Start
- Feb 2006
- Primary completion
- Nov 2006
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rasburicase in hyperuricemia and tumor lysis syndrome (TLS), sponsored by Sanofi. Primary endpoints: Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia) and Adverse events occurrence. Started Feb 2006; status: completed.
02
Drugs
rasburicase
03
Conditions
hyperuricemiatumor lysis syndrome (TLS)
Beyond the preview
Go deeper on NCT00302653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00302653.